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(Summer 1988) p. 71 for background
information.) During that three-year
period, a total of four NHAs had their
licenses revoked; seventeen NHAs had
their licenses suspended for a period of
time ranging from thirty days to one
year, and were subsequently placed on
probation; and two NHAs were placed
on probation.
RECENT MEETINGS:
At BENHA's June 12 meeting, Ray
Nikkel reported that he and Board Chair
Doug Troyer attended a meeting of the
National Association of Boards of
Examiners for Nursing Home Administrators (NAB). Of major concern to
NAB members was the status of proposed federal regulations outlining certification standards for NHAs, which were
to be released by the Health Care
Finance Administration this fall. NAB is
also conducting a study of nursing home
administrators to determine the elements
which are necessary to be successful in
that position. This study is conducted
every five years; the results are used as a
guide in the development of the national
NHA examination.
Also at the June 12 meeting, the
Board discussed the quarterly meeting
between BENHA and the American College of Health Care Administrators. The
two groups discussed ways to evaluate
BENHA's administrator-in-training program; specific proposals for improving
the program are scheduled to be presented at the next BENHA meeting. (See
CRLR Vol. 10, Nos. 2 & 3 (Spring/Summer 1990) p. 112 for background information.)
BENHA's August 24 meeting was
cancelled.
FUTURE MEETINGS:
To be announced.

BOARD OF OPTOMETRY
Executive Officer: Karen Olinger
(916) 739-4131
Pursuant to Business and Professions
Code section 3000 et seq., the Board of
Optometry is responsible for licensing
qualified optometrists and disciplining
malfeasant practitioners. The Board
establishes and enforces regulations pertaining to the practice of optometry,
which are codified in Chapter 15, Title
16 of the California Code of Regulations
(CCR). The Board's goal is to protect
the consumer patient who might be subjected to injury resulting from unsatis-
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factory eye care by inept or untrustworthy practitioners.
The Board consists of nine members.
Six are licensed optometrists and three
are members of the community at large.
MAJOR PROJECTS:
Foreign Graduates. In the 1990-91
budget bill signed on July 31, the legislature allocated $300,000 from the Board's
reserve fund to be used to develop a
refresher course for graduates of foreign
optometric schools. (See CRLR Vol. 10,
Nos. 2 & 3 (Spring/Summer 1990) p.
113; Vol. 10, No. I (Winter 1990) pp.
87-88; and Vol. 9, No. 3 (Summer 1989)
pp. 64-65 for extensive background
information.)
The money will be allocated directly
to the University of California, which
will develop the program of remedial
coursework. The program will be developed through either the Berkeley or Los
Angeles campus of the UC system. The
refresher course, once developed, will
probably be offered in Los Angeles: the
majority of foreign optometric graduates
needing remedial training live in the Los
Angeles area. The Board expects to
work closely with the University of California in the development of this program.
LEGISLATION:
The following is a status update on
bills discussed in CRLR Vol. 10. Nos. 2
& 3 (Spring/Summer 1990) at page 114:
AB 1462 (Klehs), as introduced,
would have required health care service
plans that offer optometric services to
provide a comprehensive optometric
examination. The bill also would have
prohibited the plan from scheduling
examinations for fewer than thirty minutes unless the optometrist determines
that the examination may be satisfactorily completed in fewer than thirty minutes. On August 14, the bill was substantially amended and would have required
the Department of Corporations to conduct an investigation into the practices of
health care service plans to determine
whether the practice of scheduling
appointments for less than thirty minutes
is sufficient for an appropriate and comprehensive optometric examination. This
bill was vetoed by the Governor on
September 26.
AB 2198 (Klehs), as amended March
12, would have required the Board to
hold licensure examinations at least
twice per year until January 1, 1994, and
would have limited the use of examination fees to activities related to the
license examination. This bill died in the
Senate Business and Professions Committee.
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AB 881 (Hughes), which authorizes
the Board to require proof of completion
of continuing education as a condition
for license renewal, was signed by the
Governor on September 26 (Chapter
1382, Statutes of 1990).
SB 1104 (Roberti), as amended June
21, extends until January I, 1994, the
Board's authority to refuse to honor a
doctor of optometry degree awarded by a
foreign university, if the Board determines its instruction is not equivalent to
that offered at colleges and universities
in the United States. This bill was signed
by the Governor on September 4 (Chapter 583, Statues of 1990). (See CRLR
Vol. 10, Nos. 2 & 3 (Spring/Summer
1990) p. 113; Vol. 10, No. I (Winter
1990) pp. 87-88; and Vol. 9, No. 4 (Fall
1989) p. 73 for background information
on this issue.)
LITIGATION:
On August 28, the U.S. Court of
Appeals for the District of Columbia
Circuit dealt a severe blow to "corporate
optometry" by striking down the Federal
Trade Commission's (FTC) ruling
known as "Eyeglasses 11" in California
State Board of Optometry v. Federal
Trade Commission, No. 89-1190 (D.C.
Cir. Aug. 28, 1990). (See CRLR Vol. 10,
No. I (Winter 1990) pp. 88-89 for extensive background information on this
case.) The "Eyeglasses II" ruling, which
attempted to prevent state boards of
optometry from prohibiting corporate
optometry, was the result of an FTC
investigation into state regulations which
favor the practice of optometry by the
sole practitioner over optometric practices owned by corporations. The FTC
study suggested that state restrictions on
corporate optometry have resulted in
higher- priced eye care which is not necessarily higher in quality.
The court of appeals did not decide
the merits of the FTC's "Eyeglasses II"
ruling. Instead, the court viewed this
case as raising issues of federalism: the
court held that the FTC lacks the authority to issue a ruling which abridges the
powers of the states. The court reasoned
that Congress did not intend to authorize
the FTC to limit states in their sovereign
capacities. The FTC's ruling, according
to the court, would change the balance of
power between the federal government
and the states. The court vacated the
FTC rule as an improper extension of
federal power in the absence of a congressional mandate.
This decision will likely have a
nationwide impact on the practice of corporate optometry. Unless reversed on
appeal, state boards of optometry will be
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permitted to continue adopting regulations which favor the sole practitioner
over the optometry chain/franchise.
Optometry chains will likely push for
state legislation to loosen the restrictions
on corporate optometry.
RECENT MEETINGS:
At its August 13 meeting, the Board
discussed a draft legislative proposal to
increase license and examination fees to
cover the costs of these operations; currently, the fees cover one-fourth of the
costs. The Board also discussed a proposal to regulate the retention of optometric records; currently, no statute
requires the retention of optometric
records.
The Board discussed the initiation of
an educational program to control the
practice of optometry by unlicensed
individuals. The Board indicated concern about optometric students who
begin working in an optometry practice
before receiving a license. Traditional
enforcement has not been effective in
curtailing unlicensed practice. The
Board therefore decided to issue a memorandum to optometrists reminding them
that individuals who have not yet
received a license may not practice
optometry, even if supervised by a
licensed optometrist.
The Board's legal counsel issued a
clarification on the practice of optometry
in rest homes. Mobile practice is prohibited; however, an optometrist may make
a house call to his/her own immobile
patient.
The Board has completed a consumer
pamphlet; however, as of its August 13
meeting, the Board had not yet found
funds for publication. The Board expects
to publish a newsletter to it own
licensees by the end of 1990.
FUTURE MEETINGS:
To be announced.

BOARD OF PHARMACY
Executive Officer: PatriciaHarris
(916) 445-5014
Pursuant to Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits to
pharmacists, pharmacies, drug manufacturers, wholesalers and sellers of hypodermic needles. It regulates all sales of
dangerous drugs, controlled substances
and poisons. The Board is authorized to
adopt regulations, which are codified in
Chapter 17, Title 16 of the California
Code of Regulations (CCR). To enforce
its regulations, the Board employs full-

time inspectors who investigate accusations and complaints received by the
Board. Investigations may be conducted
openly or covertly as the situation
demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, including professional misconduct and any acts
substantially related to the practice of
pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are
appointed for four-year terms.
At its May 30 meeting, the Board
announced that Patricia Harris has been
selected as its new Executive Officer.
MAJOR PROJECTS:
Investigation of Revenue Enhancement ProgramsBetween Physiciansand
Home IV Providers. The Board has
appointed a special committee to investigate the financial relationships between
physicians and home infusion companies. Although home infusion companies
are not specifically licensed by any state
agency, these relatively new service
companies contract with pharmacists, as
well as other licensed professionals, to
provide in-home intravenous (IV) therapy to specified patients. Only a pharmacist may supply medications to IV
patients on an ongoing basis; thus, the
pharmacist is an integral part of the
home IV therapy process.
It has come to the attention of the
Board that various "revenue enhancement" or kickback schemes exist
between referring physicians and home
infusion companies. Business and Professions Code sections 650 and 651 prohibit compensation or financial inducements to physicians for referrals, unless
certain criteria are met. Further, the U.S.
Inspector General is proposing various
"safe harbor" regulations, which specify
the types of financial arrangements
which are permissible without fear of
kickback prosecution. However, based
on concerns expressed by pharmacists
participating the home infusion industry,
the Board believes that certain "revenue
enhancement programs" amount to kickback violations.
The three most common financial
arrangements known to exist between
physicians and infusion companies are
as follows: (1) the infusion company is a
limited partnership in which physicians
buy shares as limited partners and share
in the profits; (2) a joint venture operation is created, which includes various
physicians as members of the joint ven-

ture; the physician contributes little to
the initial capitalization of the company,
but shares in a periodic division of the
profits; and (3) the patient's physician
acts as a "consultant" without ever actually visiting the patient at home. The
infusion company then provides the
medication and bills the patient or the
patient's insurance company. However,
payment goes directly to the physician,
who deducts up to 30% as a "consulting
fee" and forwards the remainder to the
infusion company. Much concern has
been raised over whether any legitimate
services are rendered by a physician as a
consultant, particularly when the physician never actually visits the patient personally for these "consulting" services.
Under current hospital practices, the
physician must personally visit the
patient in order to be financially compensated, even if the physician is supervising the treatment. The home infusion
situation is comparable to the hospital in
terms of the service being rendered and
the standards for compensation.
The Board of Pharmacy's major concern is that these financial relationships
are not in the best interest of the patient.
When there is a direct financial benefit at
stake, the physician may be less inclined
to prescribe an equally appropriate therapy which would cost less to the patient.
Due to the rapid increase in the home IV
industry in recent years, the Board is
concerned that many patients are receiving home IV antibiotics when oral
antibiotics would be appropriate. The
Board's special committee has identified
three major areas of focus for its investigation: (1) Is there any harm to the
patient? (2) Are these practices in the
best interest of patient care? (3) Do they
interfere with freedom of choice in
selecting health care?
In addition, the committee will
address the following issues:
-examination of section 650 of the
Business and Professions Code for interpretation and possible amendment, and
review of the proposed "safe harbor"
regulations;
-clarification of existing laws that
regulate the home IV provider industry
(including proposed regulations that will
be submitted to the Department of
Health Services for the licensure of
Home Health Agency/Home IV Drug
Therapy Providers);
-identification of legitimate services
and financial arrangements, including a
focus on the following: (a) impact on
patient care, (b) review of existing reimbursement enhancement programs and
clarification of known types of arrangements, (c) identification of legitimate
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